VolitionRx Ltd. (NYSE American: VNRX) has entered into a Research License and Exclusive Commercial Option Rights Agreement with Werfen's Immunoassay Technology Center to assess antiphospholipid syndrome (APS) using Volition's proprietary Nu.Q H3.1 Neutrophil Extracellular Traps (NETs) assay on Werfen diagnostic platforms. This collaboration represents a significant advancement in autoimmune disease diagnostics, potentially addressing critical gaps in current APS detection methods.
The partnership leverages Werfen's expertise in specialized diagnostics and its installed base of proprietary analyzers, including the ACL AcuStar platform to which the Nu.Q NETs assay has already been successfully transferred. Early results in detecting NETs levels in APS patients have shown promising outcomes, suggesting the test could serve as a valuable risk indicator for thrombosis in affected individuals. Marta Palicio, Werfen's Immunoassay Technology Center Innovation R&D Director, noted that further validation and clinical utility studies will determine the marker's potential role in improving management of this complex syndrome.
Antiphospholipid syndrome affects approximately 4 million people worldwide and is currently diagnosed through two positive antibody tests conducted at least 12 weeks apart. Volition believes its Nu.Q NETs test represents the first CE-IVD biomarker under investigation for APS, potentially offering improvements in both diagnostic decision-making and ongoing patient monitoring. The test's development aligns with Volition's focus on advancing epigenetics science through simple, cost-effective blood tests for disease detection and monitoring.
The agreement implements Volition's strategy to license its proprietary Nu.Q NETs technology to large worldwide companies that possess specific disease knowledge, product development capabilities, and regulatory experience. Gael Forterre, Chief Commercial Officer at Volition, emphasized the importance of leveraging Werfen's established platform and expertise to accelerate the test's development and potential commercialization. For more information about Volition's technology platform, visit https://www.Volition.com.
This collaboration could significantly impact the approximately 4 million individuals affected by APS worldwide by providing more efficient diagnostic tools and better management strategies for this complex autoimmune disorder. Improved detection methods may lead to earlier intervention and reduced risk of thrombosis complications, ultimately enhancing patient outcomes and quality of life for those living with APS.
